IntrinsicIntrinsic
← All summaries

Glucotrack, Inc.

GCTK
Financials & Chart →

Business Summary

Glucotrack, Inc. is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for individuals with Type 1 diabetes and Type 2 diabetes using insulin or at risk for hypoglycemia . The company was incorporated on May 18, 2010 . The global adult population suffering from diabetes was estimated at approximately 589 million in 2025, with projections to grow to approximately 853 million by 2045 . In the U.S., there were approximately 40.1 million people with diabetes in 2021, with 1.5 million new cases diagnosed in 2023 . The company believes a significant market opportunity exists for an innovative CGM device that addresses current barriers to adoption, such as inconvenience of wearing devices, discomfort of bi-weekly replacement, and aesthetic concerns, as validated by its own market research studies in 2024 and 2025 involving over 1,500 patients .

The market for CGM devices is intensely competitive, characterized by rapid change and new product introductions. Three companies, Abbott Laboratories, DexCom, and Medtronic, currently account for substantially all worldwide sales of transcutaneous CGM systems, which have sensor longevities of 7-15 days and measure glucose in interstitial fluid, leading to a 15-20 minute lag behind blood glucose readings . There is also one commercially available implantable CGM product from Senseonics Holdings, Inc., which lasts up to 365 days, is inserted under the skin of the upper arm, and requires daily fingerstick calibration after a 24-hour warm-up period . Glucotrack believes its technology, if successful, has the potential to be more accurate, more convenient, and have a longer duration than existing implantable glucose monitors .

Glucotrack's core business model is centered on the research and development of its Glucotrack CBGM. The company generates revenue through financing activities to fund its development efforts, as it has not yet commercialized its primary product candidate . Its primary customer segments, once commercialized, are Type 1 diabetes patients and Type 2 diabetes patients using insulin or at risk for hypoglycemia .

The company is developing the Glucotrack CBGM, a long-term implantable continuous blood glucose monitor. This device utilizes an intravascular approach, implanted subcutaneously with a lead placed directly into a blood vessel, to provide continuous blood glucose measurements with effectively zero lag time, unlike commercially available CGM systems that measure interstitial fluid glucose . The company has demonstrated a minimum two-year implant life is highly probable with the current sensor design, and a 3-year longevity is feasible based on in-vitro and in-silico test results . Additionally, Glucotrack has successfully demonstrated continuous glucose sensing in the epidural space, an approach that could enable integrated chronic disease management for patients contemplating spinal cord stimulation therapy, offering dual benefits of pain relief and glucose monitoring .

For the fiscal year ended December 31, 2025, the company reported a net loss of $19,388 thousand . Total operating expenses were $16,090 thousand , comprising research and development expenses of $9,813 thousand and general and administrative expenses of $6,277 thousand . Other expense, net, was $3,298 thousand . The company had cash and cash equivalents of $7,383 thousand as of December 31, 2025, and an accumulated deficit of $151,838 thousand .

Comparing fiscal year 2025 to 2024, the net loss decreased from $22,597 thousand in 2024 to $19,388 thousand in 2025, primarily due to a reduction in other expense . Research and development expenses increased by $314 thousand , from $9,499 thousand in 2024 to $9,813 thousand in 2025, mainly due to increased product design, development, manufacturing activities, and pre-clinical animal studies . General and administrative expenses increased by $1,229 thousand , from $5,048 thousand in 2024 to $6,277 thousand in 2025, driven by increased professional fees, personnel costs, and placement agent fees . Share-based compensation expense decreased from $671 thousand in 2024 to $211 thousand in 2025, attributed to a reduction in the fair value of shares issued for Board compensation and IP agreements . Other expense shifted from an income of $8,050 thousand in 2024 to an expense of $3,298 thousand in 2025, with reductions in recognized losses on debt settlement and equity issuance offset by a change in fair value of derivative liabilities .

During 2025, Glucotrack completed a first-in-human acute study for its CBGM, demonstrating device performance and safety, as well as safety of implant and removal procedures, with positive results meeting endpoints of no serious safety events and similar performance/accuracy to animal studies . Initial results were presented at the 2025 Advanced Technologies & Treatments for Diabetes annual meeting, and final results at the 2025 American Diabetes Association annual conference . The company initiated a long-term, multicenter feasibility study in Australia but later closed it due to early product learnings and planned product updates . Glucotrack also obtained ISO 13485 certification in 2024 and successfully passed its 2025 annual audit without major nonconformities . In terms of financing, the company sold 206,300 shares of Common Stock for net proceeds of $3,593 thousand in March 2025 and 414,784 shares for net proceeds of $4,320 thousand during Q2 2025 through an ATM program . A registered direct offering in February 2025 generated approximately $2,752 thousand in net proceeds from the sale of 43,968 shares . A private placement in December 2025 resulted in approximately $3,544 thousand in net proceeds from the issuance of 1,033,591 pre-funded warrants and 2,067,182 common warrants . The company also issued a promissory note in September 2025 for a purchase price of $3,000 thousand with a principal amount of $3,600 thousand .

Business Outlook

Glucotrack expects research and development expenses to increase in 2026 and beyond , primarily due to expanding clinical trial activities, hiring additional personnel, and the continued development of the Glucotrack CBGM . The company may adjust or allocate its research and development expenses based on available financial resources and commercial needs, including the FDA registration process, specific customer requirements, and the development of new Glucotrack CBGM models and other product candidates .

A major growth area for Glucotrack is the planned launch of its U.S. clinical trial program for the Glucotrack CBGM in the second half of 2026 , subject to FDA approval of its Investigational Device Exemption (IDE) submission, which is expected to be filed in the second quarter of 2026 . The company is expediting discussions with the FDA through the presub process regarding protocol study design and related requirements for IDE approval for both the initial Feasibility Study and future long-term human clinical trials in the United States . In anticipation of IDE approval, Glucotrack is collaborating with a respected physician investigator and medical institution known for conducting CGM studies . The company believes its technology, if successful, has the potential to be more accurate, more convenient, and have a longer duration than other implantable glucose monitors currently in the market or under development .

Another potential growth area is the application of its continuous glucose sensing technology in the epidural space. This approach is significant for diabetes patients already considering spinal cord stimulation therapy, as it may enable integrated chronic disease management by providing dual benefits of pain relief and glucose monitoring with one system . The company has successfully demonstrated this capability in preclinical studies and is currently working with a renowned neuromodulation physician to evaluate a clinical development program for this medical application .

The company's operational outlook includes continued efforts to strengthen internal controls. Management identified material weaknesses in internal control over financial reporting as of December 31, 2024, and concluded that controls were not effective as of December 31, 2025, due to insufficient internal accounting personnel, segregation of duties, and lack of sufficient internal controls (including IT general controls) . Remedial actions initiated in 2025 include implementing enhanced IT system access controls and data backup procedures, hiring additional accounting personnel, engaging third-party valuation and technical accounting experts, and initiating the implementation of an enterprise resource planning (ERP) system (Oracle NetSuite) to automate user roles, permissions, and approval workflows . These remediation efforts are intended to continue during fiscal year 2026 .

Glucotrack's planned capital allocation strategy involves raising additional capital through debt financings, private or public equity financings, license agreements, collaborative agreements, or other arrangements . As of December 31, 2025, the company had $7,383 thousand in cash and cash equivalents and does not expect this to be sufficient to fund operating cash flow needs for at least the next twelve months . The company raised $14,209 thousand through the sale of common stock and $3,000 thousand from the issuance of a promissory note during 2025 . The 2024 Equity Incentive Plan, as amended in May 2025, allows for the issuance of up to 125,000 shares , with 97,544 shares remaining available as of December 31, 2025 .

The company faces structural headwinds and execution risks related to its ability to secure additional financing, which, if unavailable on acceptable terms, could force delays, reductions, or elimination of clinical trials or other operations, adversely affecting operational goals . The regulatory approval process for medical devices is expensive, time-consuming, and uncertain, with no guarantee of FDA clearance or approval, especially for Class III implantable devices like the Glucotrack CBGM . The company also faces intense competition from larger medical device companies with greater resources and established market presence . Furthermore, the increasing use of GLP-1 drugs for obesity and Type 2 diabetes could potentially compete with the Glucotrack CBGM, particularly for non-insulin dependent Type 2 diabetes and pre-diabetes patients .

Risk Factors

Glucotrack faces several material risks, including a history of operating losses and an accumulated deficit of $151.8 million as of December 31, 2025, raising substantial doubt about its ability to continue as a going concern without additional financing . The company is highly dependent on the successful regulatory approval and commercialization of its primary product candidate, Glucotrack CBGM, which is not yet approved for sale in the U.S. or internationally and will likely require expensive and uncertain clinical trials for Class III device approval . Intense competition from larger medical device companies with greater financial, manufacturing, marketing, and product development resources poses a significant threat to commercial success . The market for diabetes treatment is also evolving with increasing use of GLP-1 drugs, which could compete with the Glucotrack CBGM and impact its commercialization, particularly for Type 2 diabetes patients not dependent on insulin and pre-diabetics . Operational risks include reliance on third-party manufacturers, potential delays in clinical trials due to patient recruitment or regulatory hurdles, and the risk of product liability lawsuits, for which the company currently does not maintain product liability insurance in the United States and has $10.0 million AUS Dollars per claim and in aggregate in Australia . Cybersecurity threats to its information technology infrastructure could expose the company to liability and damage its reputation . Furthermore, the company identified material weaknesses in its internal control over financial reporting as of December 31, 2025, related to insufficient accounting personnel, segregation of duties, and IT general controls, which could lead to material misstatements in financial statements . The company's common stock has experienced significant volatility, and there is a risk of delisting from Nasdaq, especially with a recently proposed rule requiring a minimum market value of listed securities of at least $5 million , which the company's common stock currently trades below .

Management Priorities

Management's message emphasizes the company's transition from development to potential commercialization, focusing on the Glucotrack CBGM as its sole product. They acknowledge the significant financial challenges, including recurring losses and an accumulated deficit of $151,838 thousand as of December 31, 2025, which raises substantial doubt about the company's ability to continue as a going concern . A key strategic priority is the advancement of the U.S. clinical trial program, with an Investigational Device Exemption (IDE) submission expected in the second quarter of 2026 and trial launch in the second half of 2026 . Management also highlights the importance of securing additional financing through various means, including equity and debt offerings, to fund operations and growth . Another strategic focus is on strengthening internal controls, as evidenced by ongoing remediation efforts for identified material weaknesses in financial reporting .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Overview
  3. [3] Item 1, Business — Market Opportunity — Diabetes
  4. [4] Item 1, Business — Market Opportunity — Diabetes
  5. [5] Item 1, Business — Market Opportunity — Glucose Monitoring
  6. [6] Item 1, Business — Competition
  7. [7] Item 1, Business — Competition
  8. [8] Item 1, Business — Overview
  9. [9] Item 1, Business — Overview
  10. [10] Item 1, Business — Overview
  11. [11] Item 1, Business — Our Product
  12. [12] Item 1, Business — Our Product
  13. [13] Item 1, Business — Our Product
  14. [14] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Net Loss
  15. [15] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Total operating expenses
  16. [16] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Research and Development Expense
  17. [17] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — General and Administrative Expense
  18. [18] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Other (Income) Expense, net
  19. [19] Item 7, MD&A — Liquidity and Going Concern
  20. [20] Item 7, MD&A — Liquidity and Going Concern
  21. [21] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Net Loss
  22. [22] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Net Loss
  23. [23] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Net Loss
  24. [24] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Research and Development Expense
  25. [25] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Research and Development Expense
  26. [26] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Research and Development Expense
  27. [27] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Research and Development Expense
  28. [28] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — General and Administrative Expense
  29. [29] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — General and Administrative Expense
  30. [30] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — General and Administrative Expense
  31. [31] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — General and Administrative Expense
  32. [32] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Share-based compensation expense
  33. [33] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Share-based compensation expense
  34. [34] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Share-based compensation expense
  35. [35] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Other (Income) Expense, net
  36. [36] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Other (Income) Expense, net
  37. [37] Item 7, MD&A — Results of Operations – Comparison of the Years Ended December 31, 2025 and 2024 — Other (Income) Expense, net
  38. [38] Item 1, Business — Overview
  39. [39] Item 1, Business — Overview
  40. [40] Item 1, Business — Overview
  41. [41] Item 1, Business — Overview
  42. [42] Item 7, MD&A — Financing Activity — ATM Sales Agreement
  43. [43] Item 7, MD&A — Financing Activity — ATM Sales Agreement
  44. [44] Item 7, MD&A — Financing Activity — ATM Sales Agreement
  45. [45] Item 7, MD&A — Financing Activity — Registered Direct Offering
  46. [46] Item 7, MD&A — Financing Activity — Registered Direct Offering
  47. [47] Item 7, MD&A — Financing Activity — Private Placement December 2025
  48. [48] Item 7, MD&A — Financing Activity — Private Placement December 2025
  49. [49] Item 7, MD&A — Financing Activity — Promissory Note
  50. [50] Item 7, MD&A — Financing Activity — Promissory Note
  51. [51] Item 7, MD&A — Operating Expenses — Research and Development
  52. [52] Item 7, MD&A — Operating Expenses — Research and Development
  53. [53] Item 7, MD&A — Operating Expenses — Research and Development
  54. [54] Item 1, Business — Overview
  55. [55] Item 1, Business — Overview
  56. [56] Item 1, Business — Our Product
  57. [57] Item 1, Business — Our Product
  58. [58] Item 1, Business — Overview
  59. [59] Item 1, Business — Overview
  60. [60] Item 1, Business — Our Product
  61. [61] Item 9A, Controls and Procedures — Management’s Report on Internal Controls Over Financial Reporting
  62. [62] Item 9A, Controls and Procedures — Management’s Remediation Measures
  63. [63] Item 9A, Controls and Procedures — Management’s Remediation Measures
  64. [64] Item 7, MD&A — Liquidity and Going Concern
  65. [65] Item 7, MD&A — Liquidity and Going Concern
  66. [66] Item 7, MD&A — Liquidity and Going Concern
  67. [67] Item 1, Note 1 — Liquidity and Going Concern
  68. [68] Item 1, Note 1 — Liquidity and Going Concern
  69. [69] Item 1, Note 1 — Liquidity and Going Concern
  70. [70] Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters — 2024 Equity Incentive Plan
  71. [71] Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters — 2024 Equity Incentive Plan
  72. [72] Item 12, Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters — 2024 Equity Incentive Plan
  73. [73] Item 7, MD&A — Liquidity and Going Concern
  74. [74] Item 1A, Risk Factors — Glucotrack CBGM is not approved for sale in the United States or other jurisdictions.
  75. [75] Item 1A, Risk Factors — If our competitors develop and market products that are more effective, safer or less expensive than Glucotrack CBGM or our future product candidates, if any, our commercial opportunities will be adversely affected.
  76. [76] Item 1A, Risk Factors — If our competitors develop and market products that are more effective, safer or less expensive than Glucotrack CBGM or our future product candidates, if any, our commercial opportunities will be adversely affected.
  77. [77] Item 1A, Risk Factors — We have a history of operating losses, and there is no assurance that we will generate material revenues or become profitable in the near future.
  78. [78] Item 1A, Risk Factors — Our independent registered public accounting firm’s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.”
  79. [79] Item 1A, Risk Factors — We are highly dependent on the success of our primary product candidate, Glucotrack CBGM, and cannot give any assurance that it will receive regulatory approval or clearance or be successfully commercialized.
  80. [80] Item 1A, Risk Factors — If our competitors develop and market products that are more effective, safer or less expensive than Glucotrack CBGM or our future product candidates, if any, our commercial opportunities will be adversely affected.
  81. [81] Item 1A, Risk Factors — If our competitors develop and market products that are more effective, safer or less expensive than Glucotrack CBGM or our future product candidates, if any, our commercial opportunities will be adversely affected.
  82. [82] Item 1A, Risk Factors — If product liability lawsuits are brought against us, we may incur substantial liabilities.
  83. [83] Item 1A, Risk Factors — If product liability lawsuits are brought against us, we may incur substantial liabilities.
  84. [84] Item 1A, Risk Factors — Security threats to our information technology infrastructure could expose us to liability and damage our reputation and business.
  85. [85] Item 1A, Risk Factors — We had identified a material weakness in our internal control over financial reporting, and we may not be able to successfully implement remedial measures.
  86. [86] Item 1A, Risk Factors — If we are unable to continue to satisfy the applicable continued listing requirements of Nasdaq, our Common Stock could be delisted, and we and our stockholders could face significant material adverse consequences.
  87. [87] Item 1A, Risk Factors — If we are unable to continue to satisfy the applicable continued listing requirements of Nasdaq, our Common Stock could be delisted, and we and our stockholders could face significant material adverse consequences.
  88. [88] Item 7, MD&A — Liquidity and Going Concern
  89. [89] Item 7, MD&A — Liquidity and Going Concern
  90. [90] Item 1, Business — Overview
  91. [91] Item 1, Business — Overview
  92. [92] Item 7, MD&A — Liquidity and Going Concern
  93. [93] Item 9A, Controls and Procedures — Management’s Remediation Measures

Analysis on 5/21/2026